What is it about?
Mesoporous silica nanoparticles for the development of stimuli-responsive DDSs has been paid close attention to. We established the redox and pH dual-stimuli responsive drug delivery system (ZnO@CMS) based on colloidal mesoporous silica nanoparticles (CMS) with ZnO QDs as capping agent in cancer therapy. The drug release from ZnO@CMS might be controlled in redox and pH dual-stimuli conditions, ZnO@CMS had better biocompatibility compared to CMS-SH and might achieve the antitumor effect on cancer cells.
Photo by Alex Stuart on Unsplash
Why is it important?
The in vitro release studies indicated the redox and pH-sensitive drug release behaviors. The hemolysis and BSA adsorption experiments showed that the modification of ZnO QDs on CMS-SH (ZnO@CMS) has better biocompatibility compared to CMS-SH. The cell viability assay exhibited that the ZnO@CMS might achieve a antitumor effect on cancer cells due to the cytotoxicity of ZnO QDs. The ZnO@CMS-DOX showed a higher cellular uptake performance in MCF-7 cells than that of CMS-DOX due to the ZnO QDS as a capping agent blocking the pores of nanoparticles and inhibiting the release of DOX. Therefore, the excellent properties of ZnO@CMS might make it the excellent redox/pH-responsive nanocarrier for broad application in tumor chemotherapy.
Read the Original
This page is a summary of: Redox/pH dual stimuli-responsive ZnO QDS-gated mesoporous silica nanoparticles as carriers in cancer therapy, IET Nanobiotechnology, May 2019, the Institution of Engineering and Technology (the IET), DOI: 10.1049/iet-nbt.2019.0031.
You can read the full text:
The following have contributed to this page